Figure 4.

Blockade of FPR1 using a pharmacological inhibitor reduces agonist‐induced platelet aggregation. The effect of different concentrations of Boc‐MLF on CRP‐XL (0.25 μg/mL)‐induced aggregation using human isolated platelets (A) or ADP (2 μmol/L)‐induced aggregation using human platelet‐rich plasma (B) was analyzed by optical aggregometry. The level of aggregation obtained with the vehicle control was taken as 100% to calculate the extent of inhibition with Boc‐MLF‐treated samples. Data represent mean ± SEM (n = 3). Similarly, the level of ATP secretion in human isolated platelets upon activation with CRP‐XL (0.25 μg/mL) in the presence and absence of different concentrations of Boc‐MLF was measured by lumiaggregometry (C). Data represent mean ± SEM (n = 3). P values shown are as calculated by 1‐way ANOVA followed by Bonferroni's correction. (*P < 0.01, **P < 0.001, and ***P <0.0001). ATP, adenosine triphosphate; CRP‐XL, cross‐linked collagen‐related peptide; FPR1, N‐formyl peptide receptor‐1; MLF, methionyl‐leucyl‐phenylalanine